The Floor Under BSX Stock Is Being Tested Again

The Floor Under BSX Stock Is Being Tested Again

Tue, August 25, 2026 at 7:05 PM GMT+3 4 min read

Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth?

Boston Scientific (BSX), a maker of medical devices from coronary catheters to neuromodulators, has seen its stock slide. Now trading around $49.01 a share, it has settled back into a price zone between $46.56 and $51.46 where buyers have, in the past, drawn a firm line. This floor has been tested and defended six separate times.

History says buyers show up here. The question every investor watching this pullback must answer is, will they this time? The table of prior bounces shows a pattern of sharp recoveries, but a pattern is not a promise. The business arriving at the floor today is what will decide if it holds or breaks.

How strong were the prior defenses?

The historical record at this level is strong. Across six previous visits to this price zone, buyers consistently stepped in to halt the decline, though the resulting rebounds were largely modest. The table of prior bounces reveals that five of the six defenses generated only single-digit to low-double-digit moves over several weeks, with just one multi-year outlier driving the historical average. The level has historically acted as support, but an immediate surge is far from guaranteed.

Other episodes were more profound. Excluding the multi-year advance that began in late 2023, the prior short-term defenses yielded a median peak gain of 8.6% across holding periods of 11 to 47 days. The October 2023 visit was a distinct outlier: rather than a quick test-and-rebound, it kicked off an extended bull run that peaked at a 122% gain nearly two years later before round-tripping back to this support band.

Why is the business arriving at this floor weaker?

A stock doesn't revisit a support level by accident. While Boston Scientific's broader business looks healthy, with trailing twelve-month revenue growth of 13.5% and a trailing GAAP price-to-earnings multiple of 19.6, specific segments are under severe pressure. Management has cut its full-year 2026 guidance for adjusted EPS to a range of $3.28 to $3.32.

The reason for the downgrade is concentrated in two former high-growth engines. Management states the U.S. market for its WATCHMAN heart device has "slowed sharply and unexpectedly, primarily driven by compounding clinical evidence, which has impacted referral patterns." At the same time, in its Electrophysiology (EP) business, the company "did not anticipate the degree of competitive share movement we're now seeing in the U.S. market." These are not minor issues; management now expects "limited adjusted EPS growth" in 2027. The company is pinning its hopes for a 2028 rebound on a new slate of products. An interesting question for investors is whether they are still holding Boston Scientific stock for its next device. For those who prefer to own the theme rather than a single name, a broader healthcare ETF like XLV offers exposure to the entire sector.

What decides if the pattern breaks?

The standoff at this level is a direct conflict between a powerful historical pattern and a newly weakened near-term business outlook. The core of the company, representing roughly 75% of revenue, is expected to grow approximately 6%. But the market is focused on the trouble spots. The one to watch is the WATCHMAN device.

Management has been explicit, guiding for global WATCHMAN growth in the second half of 2026 to be "declining mid- to high-single digits on a year-over-year basis." This is the specific trend that will likely determine whether the historical floor holds. If that rate of decline stabilizes or shows signs of bottoming, buyers may see an opportunity. If it worsens, the memory of six prior bounces may not be enough to prevent a seventh test from failing.

For more stocks testing historically significant support levels, our Buy the Dip screen monitors these inflection points daily.

One Stock At A Crossroads Should Not Decide Your Year

A stock testing its support is a stock at a decision point, and decision points cut both ways. Concentrated holders feel every one of them at full force.

The Trefis High Quality (HQ) Portfolio spreads those moments across roughly 30 quality businesses in different industries, so no single stock's crossroads decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Follow the drama; diversify the stakes.